1279P First-line Lorlatinib Vs Crizotinib in Asian Patients with ALK+ Non-Small Cell Lung Cancer (NSCLC): 5-Year Outcomes from the CROWN StudyY-L. Wu,H.R. Kim,R.A. Soo,Q. Zhou,H. Akamatsu,G-C. Chang,C.H. Chiu, H. Hayashi,S-W. Kim,Y. Goto, T. Kato, J. Zhou,V.H.F. Lee, M. Nishio,B. Han,D-W. Kim, S. Lu,A. Polli,J-F. Martini,T.S.K. MokAnnals of Oncology（2024）引用 0|浏览2AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
